Shanghai, China

Suzhen Dong


 

Average Co-Inventor Count = 8.0

ph-index = 1


Company Filing History:


Years Active: 2020

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Innovations of Suzhen Dong in Antibacterial and Antitumor Research

Introduction

Suzhen Dong is a notable inventor based in Shanghai, China. He has made significant contributions to the field of pharmaceuticals, particularly in the development of new antibacterial and antitumor agents. His innovative work focuses on spiro three-membered and five-membered ring peptide deformylase inhibitors.

Latest Patents

Suzhen Dong holds a patent for a spiro three-membered ring and spiro five-membered ring peptide deformylase inhibitor. This invention demonstrates antibacterial activity against antibiotic-resistant Gram-positive strains by inhibiting the peptide deformylase necessary for bacterial protein synthesis. Additionally, it shows promise in promoting apoptosis in various cancer cell strains, including colorectal cancer, leukemia, lung cancer, and breast cancer, among others. The patent highlights the selective action of these inhibitors, which do not interfere with human protein synthesis while effectively targeting bacterial cells.

Career Highlights

Throughout his career, Suzhen Dong has worked with reputable companies such as Rudong Ruien Pharmaceutical Technology Co. Ltd and Guangdong Hebo Pharmaceutical Co., Ltd. His experience in these organizations has contributed to his expertise in pharmaceutical innovations and research.

Collaborations

Suzhen Dong has collaborated with notable colleagues, including Wenhao Hu and Fengping Lv. These partnerships have likely enhanced his research capabilities and broadened the impact of his inventions.

Conclusion

Suzhen Dong's innovative work in developing peptide deformylase inhibitors represents a significant advancement in the fight against antibiotic resistance and cancer. His contributions to the pharmaceutical field continue to pave the way for new therapeutic options.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…